Jacobson Pharma Corporation Ltd. has issued a positive profit alert, indicating that the group expects a significant increase in profit from continuing operations for the fiscal year ending 31 March 2025 (FY2025). Based on a preliminary review of the unaudited consolidated management accounts for FY2025 and the information currently available, the company anticipates a more than 40% rise in profit from continuing operations compared to the previous fiscal year ending 31 March 2024. The anticipated profit increase is primarily attributed to strong performance in both the specialty medicines and overall generic drug business. Additionally, revenues were bolstered by contributions from newly in-licensed products and the successful launch of new products. Improved operating leverage across production facilities and financial savings from effective cost control measures also played a role in the profit growth. Furthermore, as a result of no longer consolidating the results of JBM Healthcare Limited following the distribution of its shares as a special dividend in August 2023, the profit attributable to equity shareholders for FY2025 is expected to grow by over 10% compared to the previous fiscal year. The consolidated results for FY2025 have yet to be finalized, and further details of the Group's performance will be disclosed in the annual results announcement expected to be published on 13 June 2025. Shareholders and potential investors are advised to exercise caution when dealing in the company's shares.